amoxicillin / Generic mfg. - LARVOL DELTA

Assessing Knowledge, Attitude, and Practices of Dentists on Antibiotic Use for Pediatric Dental Infections in Bangladesh: A Cross-Sectional Study. (PubMed, Health Sci Rep) - "Amoxicillin, azithromycin, and clindamycin were the antibiotics most commonly prescribed. Awareness of AMR is high, but this awareness does not consistently translate into cautious prescribing. Structured antibiotic stewardship guidance for paediatric dental practice is needed."

Journal • Observational data • Infectious Disease • Pediatrics

Unsupervised machine learning for multi-system adverse event pattern detection in pharmacovigilance: A proof-of-concept analysis of fluoroquinolone reports in FAERS. (PubMed, Br J Clin Pharmacol) - "Unsupervised clustering of FAERS data identified, without prior clinical input, a reproducible multi-system adverse-event pattern among fluoroquinolone reports, potentially supporting the feasibility of unsupervised exploratory pattern detection in pharmacovigilance. Given the limitations of spontaneous reporting databases, the findings are strictly hypothesis-generating."

Adverse events • Journal • Alzheimer's Disease • CNS Disorders • Dry Eye Disease • Muscular Atrophy • Musculoskeletal Diseases • Ophthalmology • Psychiatry

Efficacy and Safety of P-CABs-Based Bismuth Quadruple Therapy for First-line Helicobacter pylori Eradication: A Real-World Evidence Study. (PubMed, Int J Antimicrob Agents) - "P-BcQT demonstrated promising efficacy as a first-line H. pylori treatment regimen. However, regimens containing clarithromycin or levofloxacin appear less effective. Future optimization may focus on shorter treatment durations, personalized dosing adjustments and regional resistance patterns."

HEOR • Journal • Real-world evidence • Infectious Disease

Listeria monocytogenes and spondylodiscitis : a review of literature and presentation of a clinical case. (PubMed, Diagn Microbiol Infect Dis) - "Blood culture revealed Lm bacteremia; intravenous amoxicillin monotherapy was therefore initiated...In the absence of neurological symptoms, gentamicin was not added. Following a positive clinical response achieved through three weeks of intravenous therapy, oral regimen with trimethoprim-sulfamethoxazole was prescribed for an additional three weeks. This short course of parenteral antibiotherapy allowed earlier discharge with good safety and tolerance. In the absence of treatment guidelines for Lm spondylodiscitis, this successful approach highlights the possibility of an earlier switch to oral treatment."

Journal • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain

Two birds, one stone: Concurrent control of chronic plaque psoriasis and pouchitis with tildrakizumab therapy (EADV 2026) - "Prior therapies, including ultraviolet phototherapy, topical calcipotriol/betamethasone dipropionate gel, cyclosporine and adalimumab, provided suboptimal disease control. Concurrently, his pouchitis was causing recurrent diarrhoea and cramping, necessitating triple antibiotic cycling (amoxicillin, cephalexin and ciprofloxacin) and colonoscopic surveillance...Clinical efficacy of ustekinumab, another IL-12/23 inhibitor, in autoimmune pouchitis further supports the mechanistic plausibility of selective IL-23 blockade in managing these coexisting autoimmune inflammatory conditions. This case highlights the potential utility of tildrakizumab in patients with overlapping systemic autoimmune-mediated disorders, underscoring the need for further mechanistic and clinical evaluation."

Dermatology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Mucositis • Plaque Psoriasis • Psoriasis • Ulcerative Colitis • IL12A • IL23A

Extensive Antibiotic Exposure and Limited Use of Biologic Therapy in Hidradenitis Suppurativa: A Multicenter Real-World Study (EADV 2026) - "Overall, 77.9% had received systemic antibiotics, most commonly doxycycline (45%), amoxicillin (43%), clindamycin (26%), and clindamycin–rifampin (14.3%), often as repeated courses. The relatively low use of biologic therapy in the context of moderate-to-severe disease suggests a gap between disease burden and treatment patterns. These findings support the need for earlier diagnosis and timely escalation to appropriate therapies to improve patient outcomes."

Clinical • Real-world • Real-world evidence • Dermatology • Hidradenitis Suppurativa • Immunology

PLEVA Triggered by Upper Respiratory Tract Infection: A Clinicopathological Approach (EADV 2026) - "In this case, the preceding respiratory infection and amoxicillin use likely served as immunological triggers...Therapeutic management remains largely empirical; however, tetracyclines and NB-UVB phototherapy have demonstrated consistent efficacy in controlling inflammatory activity and promoting lesion resolution. Conclusion This case reinforces the value of an integrated clinicopathological approach in diagnosing PLEVA and highlights the role of infectious and pharmacological triggers in its pathogenesis. A multimodal strategy combining systemic antibiotics and NB-UVB phototherapy proved effective, supporting its use as a reliable option for achieving clinical remission."

Clinical • Hematological Disorders • Immunology • Infectious Disease • Pruritus • Respiratory Diseases

VI Spanish Consensus Conference on the treatment of Helicobacter pylori infection. (PubMed, Gastroenterol Hepatol) - "As first-line treatment, a 10-day regimen with a proton pump inhibitor plus bismuth, tetracycline, and metronidazole (Pylera®) is recommended. After failure of this regimen, a combination of a proton pump inhibitor, amoxicillin, levofloxacin, and bismuth is recommended. This consensus also provides a detailed review of other rescue treatment alternatives."

Clinical guideline • Journal • Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Oncology • Peptic Ulcer • Solid Tumor

Furuncular Myiasis by Dermatobia hominis: The Challenge of Differential Diagnosis in Recalcitrant Scalp Abscesses (EADV 2026) - "Prior treatment with an 11-day course of amoxicillin for suspected bacterial cellulitis had failed...This approach minimizes neurosurgical risks, reduce the patient's discomfort and ensures complete removal. Recognizing this entity is crucial for early diagnosis and avoiding unnecessary prolonged antibiotic therapy."

Infectious Disease • Pruritus • CRP

Reactive Infectious Mucocutaneous Eruption (RIME) Successfully Treated With Upadacitinib in Three Adolescents (EADV 2026) - "Management remains non-standard, relying on supportive care, antibiotics, and heterogeneous systemic immunomodulators including corticosteroids, cyclosporine, intravenous immunoglobulin, or tumor necrosis factor inhibitors...He received azithromycin x 5 days, clobetasol propionate 0.05% ointment, and upadacitinib 15 mg daily x 14 days...Case 3: A 13-year-old female presented 3 weeks post infectious respiratory symptoms and empiric treatment with amoxicillin, clarithromycin, doxycycline, and systemic corticosteroid...She received upadacitinib 15 mg daily x 14 days, lidocaine mouthwash, and zinc supplementation...Furthermore it is fast-acting, non-injectable, outpatient-administered, and does not require laboratory monitoring. Prospective studies should validate efficacy, refine dosing/timing, assess long-term safety (including infection reactivation), and compare against standards—potentially establishing upadacitinib as first-line for suitable patients without..."

Conjunctivitis • Hematological Disorders • Infectious Disease • Mucositis • Ocular Infections • Ocular Inflammation • Ophthalmology • CRP

Acute Generalized Exanthematous Pustulosis in Childhood and Pancreatitis: A Rare but Possible Systemic Involvement – A Case Report (EADV 2026) - "The eruption was preceded by an episode of pharyngitis for which he had been treated with amoxicillin, along with antiemetic therapy and paracetamol, initiated 48 hours prior to the onset of the rash...Although this association is uncommon, it requires multidisciplinary management and careful follow-up. Further research is needed to better understand the pathophysiological mechanisms underlying this association and to optimize therapeutic strategies."

Case report • Clinical • Eosinophilia • Immunology • Pancreatitis

Glove-and-Sock Desquamation Following Streptococcal Pharyngitis in a 63-Year-Old Man: A Reminder of Scarlet Fever in the Elderly Introduction (EADV 2026) - "The patient was treated with oral amoxicillin...Conclusion Post-streptococcal desquamation can occur in elderly patients without a clinically apparent preceding rash. ASO titers should be obtained in any patient with unexplained acral desquamation following pharyngitis, regardless of age."

Clinical • Glomerulonephritis • Immunology • Infectious Disease • Lupus Nephritis • Nephrology • Otorhinolaryngology • Pruritus • Septic Shock • CRP

β-Lactam-Induced Encephalopathy: An Underrecognized Complication Of Commonly Used Antibiotics-A Case Report. (PubMed, Infection) - "β-lactam-induced encephalopathy is an underrecognized but clinically significant adverse drug reaction. Increased awareness of this condition may facilitate earlier diagnosis and prompt discontinuation of the offending agent."

Journal • CNS Disorders • Immunology • Movement Disorders • Psychomotor Agitation • Renal Disease • Septic Shock

VI Spanish Consensus Conference on the treatment of Helicobacter pylori infection. (PubMed, Rev Esp Enferm Dig) - "As first-line treatment, a 10-day regimen with a proton pump inhibitor plus bismuth, tetracycline, and metronidazole (Pylera®) is recommended. After failure of this regimen, a combination of a proton pump inhibitor, amoxicillin, levofloxacin, and bismuth is recommended. This consensus also provides a detailed review of other rescue treatment alternatives."

Journal • Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Oncology • Peptic Ulcer • Solid Tumor

Short Versus Standard Amoxicillin for Pediatric Strep Throat (clinicaltrials.gov) - P4 | N=1500 | Not yet recruiting | Sponsor: The University of Texas Health Science Center, Houston

New P4 trial • Pediatrics

Perioperative Anaphylaxis Complicated by Myocardial Infarction: A Case of Kounis Syndrome (ASA 2026) - "We present a 63‑year‑old male with a history of amoxicillin allergy undergoing elective CABG who developed catastrophic cardiovascular collapse immediately after cefazolin administration. The clinical presentation was most consistent with an anaphylaxis‑associated myocardial infarction (Kounis syndrome), illustrating the lethal intersection of perioperative anaphylaxis, coronary ischemia, and malignant arrhythmias. This case underscores the diagnostic and therapeutic complexity of managing anaphylactic myocardial infarction, where epinephrine use, mechanical circulatory support, and urgent revascularization must be balanced against ongoing inflammatory and ischemic injury."

Clinical • Cardiovascular • Hypotension • Immunology • Myocardial Infarction

Susceptibility-Guided Triple Therapy Achieves High Helicobacter pylori Eradication Regardless of Duration. (PubMed, J Gastroenterol Hepatol) - "Among patients with clarithromycin-susceptible strains receiving tailored triple therapy, eradication rates did not differ significantly according to treatment duration. However, these findings should be interpreted cautiously because the study may have been underpowered to detect modest but clinically meaningful differences. Amoxicillin susceptibility may be associated with eradication outcomes, although the statistical robustness of this association remains limited."

Journal • Infectious Disease

Helicobacter pylori eradication treatment dispensing in the Irish General Medical Services population from 2012 to 2022: a repeated cross-sectional analysis. (PubMed, Int J Clin Pharm) - "Increasing use of 14-day eradication treatments and esomeprazole suggests improving alignment with clinical guidelines. Continued reliance on clarithromycin-based triple therapy, minimal bismuth quadruple therapy use, and potential PPI duplication highlight opportunities for medicines optimisation."

Journal • Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Oncology • Peptic Ulcer • Solid Tumor

REAL-WORLD EFFECTIVENESS OF FIRST-LINE HELICOBACTER PYLORI THERAPIES ACROSS EUROPE: A 13-YEAR MULTINATIONAL ANALYSIS OF 68,361 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG) (UEGW 2026) - " A total of 68,361 treatments from 39 countries were analysed: clarithromycin-based triple therapy with amoxicillin/metronidazole (triple-CA/M, n=23,903, 35%), bismuth-based quadruple therapy with metronidazole–tetracycline (quad-sc/BMTc: single-capsule and traditional format, n=12,716, 19%), concomitant quadruple therapy with clarithromycin–amoxicillin–tinidazole/metronidazole (conco-CAT/M, n=11,024, 16%), clarithromycin–amoxicillin–bismuth quadruple therapy (quad-CAB, n=9,061, 13%), sequential quadruple therapy with CAT/M (seq-CAT/M, n=3,643, 5%), and others (n=8,014, 11%). In European clinical practice, the quad-sc/BMTc, conco-CAT/M and quad-CAB achieved >90% effectiveness, but were associated with lower tolerability. The key determinants of eradication success were adequate adherence, standard/high PPI doses, and treatment durations of 10–14 days."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Infectious Disease

REAL-WORLD EFFECTIVENESS OF FIRST-LINE HELICOBACTER PYLORI THERAPIES IN GERMANY: ERADICATION OUTCOMES IN A LOW CLARITHROMYCIN-RESISTANCE SETTING USING DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG) (UEGW 2026) - "Clarithromycin-amoxicillin triple therapy (Triple-CA, 53%) and bismuth-metronidazole-tetracycline quadruple therapy in the single-capsule formulation (Pylera®, 43%) were the predominant first-line regimens. In Germany, empirical first-line H. pylori therapy achieves excellent eradication rates when optimized 10-day regimens are used. Comparable outcomes between Triple-CA and Pylera® may be explained by the relatively low clarithromycin resistance rates reported in Germany. Beyond dyspepsia and peptic ulcer disease, GC prevention already represents a relevant indication in German routine clinical practice."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Dyspepsia • Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Peptic Ulcer • Solid Tumor

EFFICACY AND SAFETY OF ADJUVANT THERAPY WITH REBAMIPIDE IN HELICOBACTER PYLORI INFECTION: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG) (UEGW 2026) - "In real-world Russian clinical practice, the addition of rebamipide to the standard triple therapy with amoxicillin-clarithromycin and bismuth quadruple therapy with amoxicillin-clarithromycin significantly increased treatment effectiveness without affecting patient compliance. However, tolerability was poorer with rebamipide, suggesting that its use should be adapted to individual patient characteristics and clinical circumstances."

Clinical • Gastroenterology • Gastrointestinal Disorder • Infectious Disease

FIRST-LINE EMPIRICAL ERADICATION THERAPY FOR HELICOBACTER PYLORI INFECTION: EXPERIENCE FROM 1,500 CASES OF THE BRAZILIAN REGISTRY ON H. PYLORI MANAGEMENT (HP-BRAREG/WORKDHPREG) (UEGW 2026) - "Low-, standard-, and high-dose proton pump inhibitors (PPIs), as well as vonoprazan (VPZ), were used in 31%, 40%, 18%, and 11% of cases, respectively...Table 1 shows the main regimens and their eradication rates (ERs): PPI-clarithromycin(C)-amoxicillin(A) (85% of cases; ER 78%; reference category for comparison), VPZ-C-A (6%; ER 86%; OR 1.70; 95% CI 0.95-3.04) and VPZ-A (4%, ER 97%; OR 17.80; 95% CI 2.46-129)... The effectiveness of PPI-C-A for H. pylori eradication in Brazil was suboptimal (78%); VPZ-C-A might represent an alternative, with cure rates ≈90%. However, VPZ-A was the only regimen achieving >90% effectiveness."

Clinical • Dyspepsia • Immunology • Infectious Disease • Peptic Ulcer

OUTCOMES OF FIRST-LINE EMPIRICAL HELICOBACTER PYLORI ERADICATION THERAPY IN AUSTRIA: DATA FROM THE EUROPEAN REGISTRY ON THE MANAGEMENT OF H. PYLORI INFECTION (HP-EUREG) (UEGW 2026) - "The most commonly prescribed regimens, all combined with a proton pump inhibitor (PPI), were non-bismuth quadruple concomitant therapy with amoxicillin, clarithromycin and metronidazole (concomitant-ACM) (70%), three-in-one single-capsule therapy (Pylera®), consisting of bismuth, tetracycline, and metronidazole (16%), and standard triple therapy with amoxicillin and clarithromycin (triple-AC) (5%)...PPIs were administered at low (4.5 to 27 mg omeprazole equivalents b.i.d.), standard (32 to 40 mg omeprazole equivalents b.i.d.), and high doses (54 to 128 mg omeprazole equivalents b.i.d.) in 88%, 5%, and 7%, respectively... In Austria, concomitant-ACM and Pylera® achieved optimal eradication rates (≥90%) in a real-world clinical setting, supporting their continued use as empirical first-line options. Treatment duration appeared to have a greater impact on eradication success than PPI dose. As antibiotic resistance rates continue to rise worldwide, regular..."

Clinical • Dyspepsia • Gastric Cancer • Infectious Disease • Peptic Ulcer • Solid Tumor

EFFECTIVENESS OF FIRST-LINE EMPIRICAL HELICOBACTER PYLORI TREATMENT OUTSIDE EUROPE: RESULTS OF 15,000 CASES FROM THE WORLD-WIDE REGISTRY ON H. PYLORI MANAGEMENT (WORLDHPREG) (UEGW 2026) - "Overall effectiveness was 86%, reaching approximately 90% with bismuth-based quadruple therapies including: amoxicillin-levofloxacin (96%; OR 4.82; 95% CI 3.2–7.27); metronidazole-tetracycline, either as a single-capsule formulation (94%; OR 7.66; 4.93–11.91) or as a traditional regimen (89%; OR 2.32; 1.48–3.36); amoxicillin-metronidazole (94%; OR 3.52; 2.18–5.68); and amoxicillin-doxycycline (97%; OR 8.02; 3.26–19.7). Outside Europe, most bismuth-based quadruple therapies achieve ≥90% effectiveness, whereas dual amoxicillin therapy and concomitant quadruple therapy with amoxicillin-clarithromycin-metronidazole do so only in specific regions. Adherence, treatment duration of ≥10–14 days, and the use of PCABs are associated with higher eradication success."

Clinical • Infectious Disease

EFFECTIVENESS OF REUSE OF HELICOBACTER PYLORI ERADICATION THERAPIES AFTER PRIOR FAILURE: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG) (UEGW 2026) - "The most frequently reused therapies were triple therapy with amoxicillin-clarithromycin (Triple-CA), quadruple concomitant therapy with clarithromycin-amoxicillin-metronidazole (Conco-CAM), and bismuth-containing quadruple therapies with clarithromycin-amoxicillin (Quad-CAB) and metronidazole-tetracycline, either as a single-capsule formulation (Pylera®) or as a classical formulation. In real-world European clinical practice, repeated use of bismuth-containing quadruple therapies in 2nd line rescue therapy achieved relatively high eradication rates, particularly with longer treatment durations (10-14 days). Empirical reuse of these regimens may be considered when alternative options are unavailable or not feasible."

Infectious Disease